Stockreport

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Inc. Class A  (NUVB) 
PDF NUV-1511 is the Company’s first drug-drug conjugate (DDC) to enter the clinic NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company t [Read more]